• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 5. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312

Research Brief on Ketoprofen-d (CAS: 1219805-29-4): Analytical and Pharmacological Insights

Ketoprofen-d, a deuterium-labeled analog of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen (CAS: 1219805-29-4), has emerged as a critical tool in pharmacokinetic and bioanalytical research. Recent studies highlight its utility as an internal standard in mass spectrometry-based assays, owing to its near-identical chemical properties to unlabeled ketoprofen while providing distinct mass spectral signatures. This isotopic labeling minimizes matrix effects and enhances quantification accuracy in complex biological matrices such as plasma, urine, and synovial fluid.

A 2023 Journal of Chromatography B study validated a novel UHPLC-MS/MS method using Ketoprofen-d for simultaneous quantification of NSAIDs in rheumatoid arthritis patients. The method achieved a lower limit of quantification (LLOQ) of 0.1 ng/mL with <15% RSD, demonstrating superior performance over traditional non-isotopic internal standards. Researchers emphasized Ketoprofen-d's stability under long-term storage (-80°C for 6 months) and freeze-thaw cycles, making it ideal for longitudinal clinical studies.

Pharmacologically, deuterium substitution at the α-carbon (1219805-29-4) has shown intriguing metabolic effects. Drug Metabolism and Disposition (2024) reported a 2.3-fold increase in half-life (t_?) compared to native ketoprofen in human liver microsomes, attributed to the kinetic isotope effect slowing CYP2C9-mediated oxidation. This property is being explored in deuterated drug development programs, though Ketoprofen-d itself remains primarily an analytical reagent due to regulatory constraints on deuterated therapeutics.

Emerging applications include its use in dermal absorption studies, where a 2024 European Journal of Pharmaceutical Sciences paper employed Ketoprofen-d in Franz cell experiments to differentiate topical versus systemic drug penetration. The study revealed stratum corneum retention patterns undetectable with conventional methods, showcasing the compound's value in transdermal drug delivery research.

Supply chain analyses indicate growing demand for GMP-grade Ketoprofen-d, particularly from CROs conducting FDA/EMA-compliant bioequivalence studies. Current synthesis protocols (e.g., Pd-catalyzed deuterium exchange on ketoprofen precursors) yield ≥98% isotopic purity, though cost remains a barrier for widespread adoption in resource-limited settings. Future research directions include exploring its potential as a tracer in PET imaging studies through further isotopic modifications.

• 22071-22-3(Desmethyl Ketoprofen)
• 43153-07-7(2-(4-formylphenyl)propanoic acid)
• 57495-14-4(Benzeneacetic acid,3-benzoyl-a-methyl-, sodium salt (1:1))
• 22161-81-5(S-(+)-Ketoprofen)
• 67232-48-8(Benzeneacetic acid, 3-benzoyl-α-methyl-, copper(2+) salt (2:1))
• 22410-97-5(4-benzoyl-a-methyl-Benzeneacetic acid,)
• 10271-33-7(2-(2-benzoylphenyl)-2-methylpropanoic acid)
• 22071-15-4(Ketoprofen)
• 56105-81-8((R)-(-)-Ketoprofen)
• 107257-20-5(rac-4’-Methyl Ketoprofen)